Cochrane · systematic review · CD009806
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
Brunelli, MJunqueira, Atallah, ÁN, da Silva, EMK · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 5 · 71.4%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings
Population: children and adults with mucopolysaccharidosis type VI
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
12MWT: change from baseline in m walked | no estimate extracted | 1 study · 38 participants | Very low Downgraded: risk of bias, indirectness |
3MSC: change in 3MSC rates (stairs/min) from baseline | no estimate extracted | 1 study · 38 participants | Very low Downgraded: risk of bias, indirectness |
6MWT: change from baseline in m walked | no estimate extracted | 1 study · 38 participants | Very low Downgraded: risk of bias, indirectness |
Respiratory tests: absolute change from baseline in FVC (L) | no estimate extracted | 1 study · 38 participants | Very low Downgraded: risk of bias, indirectness |
Cardiac function  | no estimate extracted | NR | No studies |
GAG level: change in urinary GAG level from baseline ųg/mg creatinine | no estimate extracted | 1 study · 38 participants | Low Downgraded: risk of bias, indirectness |
AEs: drug‐related AEs | RR 1.93 [0.89, 4.17] | 1 study · 39 participants | Very low Downgraded: risk of bias, indirectness |